Detailed Information
Cited 65 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.
- Authors
- Zhu, Andrew X.; Kang, Yoon-Koo; Yen, Chia-Jui; Finn, Richard S.; Galle, Peter R.; Llovet, Josep M.; Assenat, Eric; Brandi, Giovanni; Lim, Ho Yeong; Pracht, Marc; Rau, Kun-Ming; Merle, Philippe; Motomura, Kenta; Ohno, Izumi; Daniele, Bruno; Shin, Dongbok; Gerken, Guido; Abada, Paolo; Hsu, Yanzhi; Kudo, Masatoshi
- Issue Date
- May-2018
- Publisher
- AMER SOC CLINICAL ONCOLOGY
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.36, no.15
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 36
- Number
- 15
- ISSN
- 0732-183X
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - ETC > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.